Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

Sandisk Corporation, the maker of flash drives and memory cards, debuted a new logo today, and it’s based on a single pixel. “It all started with the pixel, which is the fundamental smallest ...

CARsgen Therapeutics’ CAR-T improved progression-free survival (PFS) compared to approved therapies for patients with advanced stomach cancer in a phase 2 trial. The open-label study assessed ...

Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...

As WWE prepares for Monday Night Raw's move to Netflix on Jan. 6, Chief Content Officer Paul "Triple H" Levesque revealed the new logo for the company's flagship show in a hype video on social media.

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. The latest contender is Reviva Pharmaceuticals’ brilaroxazine, which ...

BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed to improve symptoms in a phase 1/2 trial. The drug, zilurgisertib, is ...

Worm-inspired biotech Holoclara has had a busy year. After announcing a $16 million series A round in June, the Pasadena, California, company has now dosed the first patient in a phase 1 trial of ...

Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop.

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral asset—dubbed minzasolmin—missed the study’s ...